ArticleBioinformatics (Oxford, England)2026
DiSPA: differential substructure-pathway attention for drug response prediction.
Article in Bioinformatics (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
motivationAccurate prediction of drug response in precision medicine requires models that capture how specific chemical substructures interact with cellular pathway states. However, most existing deep learning approaches treat chemical and transcriptomic modalities independently or combine them only at late stages, limiting their ability to model fine-grained, context-dependent mechanisms of drug action. In addition, vanilla attention mechanisms are often sensitive to noise and sparsity in high-dimensional biological networks, hindering both generalization and interpretability.
resultsWe present Differential Substructure-Pathway Attention (DiSPA), a framework that models bidirectional interactions between chemical substructures and pathway-level gene expression. DiSPA introduces differential cross-attention to suppress spurious associations while enhancing context-relevant interactions. On the GDSC benchmark, DiSPA achieves state-of-the-art performance, with strong improvements in the disjoint setting. These gains are consistent across random and drug-blind splits, suggesting improved robustness. Analyses of attention patterns indicate more selective and concentrated interactions compared to standard cross-attention. Exploratory evaluation shows that differential attention better prioritizes predefined target-related pathways, although this does not constitute mechanistic validation. DiSPA also shows promising generalization on external datasets (CTRP) and cross-dataset settings, although further validation is needed. It further enables zero-shot application to spatial transcriptomics, providing exploratory insights into region-specific drug sensitivity patterns without ground-truth validation. AVAILABILITY AND IMPLEMENTATION: Source code and data are available at https://github.com/sslim-aidrug/DiSPA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.